Form 4: Humana Executive Dintenfass Reports Stock Transactions

Humana's President of Enterprise Growth, David Dintenfass, reported the acquisition of 2,032 common shares and the disposal of 918 shares for tax liability on vested restricted stock units.

Summary

• David Dintenfass, President, Enterprise Growth at Humana Inc., acquired 2,032 shares of Humana Common Stock on December 15, 2025, at a price of $0.
• On the same date, Dintenfass disposed of 918 shares of Humana Common Stock at a price of $270.155 per share.
• The disposed shares were used to cover tax liabilities related to restricted stock units that vested on December 15, 2025.
• Following these transactions, Dintenfass beneficially owns 15,316 shares of Humana Common Stock directly.
• This beneficial ownership includes 11,202 restricted stock units (RSUs) which represent a contingent right to receive one share of Humana Inc. common stock each.
• Dintenfass also holds options to purchase 51,389 shares of Humana Common Stock at an exercise price of $367.21, which expire on February 21, 2031.
• These options were granted on February 21, 2024, and vest in three annual increments from February 21, 2025, to February 21, 2027.

Sentiment

Score: 6

Explanation: The transactions reflect routine executive compensation activities, including the vesting of restricted stock units and the exercise of options, followed by a tax-related sale. The net effect on direct share ownership is a slight increase from the option exercise, but the tax sale is a neutral, expected event. The overall sentiment is moderately positive due to the executive's continued accumulation of equity through compensation plans.

Positives

• Acquisition of 2,032 Humana Common shares, increasing direct equity ownership.
• Holding options to purchase 51,389 shares, indicating potential future equity ownership.
• Vesting of restricted stock units, which is a form of compensation and increases the executive's equity stake.

Negatives

• Disposal of 918 shares to cover tax liability, resulting in a reduction of direct share count.

Stakeholder Impact

• Shareholders: The transactions represent routine executive compensation and tax planning, which is generally expected and does not indicate a significant shift in company strategy or performance.
• Employees: No direct impact mentioned.
• Customers: No direct impact mentioned.
• Suppliers: No direct impact mentioned.
• Creditors: No direct impact mentioned.

Next Steps

• Further annual vesting of stock options on February 21, 2026, and February 21, 2027.

Key Dates

Recommendation

This Form 4 filing details routine insider transactions related to executive compensation, specifically the vesting of restricted stock units, the exercise of options, and the subsequent sale of shares to cover tax liabilities. Such transactions are common and do not typically provide new fundamental information about the company's operational performance or future prospects that would warrant a change in investment recommendation. Therefore, a 'hold' recommendation is appropriate, maintaining current positions based on broader company fundamentals rather than these specific insider filings.

Keywords

Humana, HUM, David Dintenfass, Insider Trading, Form 4, Stock Options, Restricted Stock Units, Equity Compensation, Executive Compensation